Purpose Polyamines are essential for normal growth; however, the requirement for, and the metabolism of, polyamines are frequently dysregulated in cancer. Polyamine analogues have demonstrated promising preclinical results in multiple model systems of cancer, but their clinical utility has been limited by apparent toxicity. A representative compound of a new generation of short chain, conformationally restricted polyamine analogues, CGC-11047 has been synthesized and ongoing phase I clinical trials indicate it to be well tolerated at weekly doses of 610 mg (dose escalation is still in progress). Therefore, studies were designed to gain a better understanding of its eVects on cellular polyamine biochemistry and eYcacy in the treatment of human lung cancer models in vitro and in vivo. Methods Human lung cancers cell lines representing nonsmall cell and small cell lung cancers were investigated for their growth and biochemical response to CGC-11047. EVects of in vitro treatment with CGC-11047 on cell growth, the activity of the polyamine biosynthetic enzyme ornithine decarboxylase (ODC), and the expression and activity of the polyamine catabolic enzymes spermidine/ spermine N 1 -acetyltransferase (SSAT) and spermine oxides (SMO) were measured. Additionally, the overall eVects on intracellular polyamine pools were monitored. Finally, the in vivo eYcacy of CGC-11047 in the treatment of a nude mouse model of human non-small cell lung cancer was evaluated.
Introduction
The natural polyamines, putrescine, spermidine, and spermine are small polycationic alkylamines that have been shown to be essential for cell growth. Polyamine concentrations are increased and polyamine metabolism dysregulated in multiple tumor cell types, thus making this pathway a rational target for antineoplastic therapies [10, 20, 28, 34] . Targeting the key enzymes involved in the polyamine biosynthetic pathway, ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC) has been demonstrated to be successful as a means of targeting polyamines and regulating cell growth, but has had limited clinical success [2, 33, 38] . In an attempt to overcome the shortcomings of the inhibitors of polyamine biosynthesis, several groups have synthesized and tested polyamine analogues that were designed to take advantage of the self-regulatory properties of the natural polyamines [4, 18, 26, 55] .
In addition to having the expected results of down-regulating biosynthesis, several analogues of spermine were found to have the unusual property of super-inducing the polyamine catabolic enzyme spermidine/spermine N 1 -acetyltransferase (SSAT) which results in the depletion of intracellular polyamines, inhibits cell growth, and in a tumor type-speciWc manner, induces apoptotic cell death [11, 15, 23, 29, 35, 41] . N 1 .N 12 -Bisethylspermine (BESpm), a symmetrically substituted spermine analogue has been previously shown to induce SSAT to very high levels in numerous tumor cell types, leading to a rapid cytotoxic response of the cells. [16] . Despite impressive in vitro activity, BESpm was not eVective in xenograft models of various tumor types [6] . A closely related analogue, N 1 , N
11
-diethylnorspermine (DENSpm), demonstrated very similar in vitro eVects with respect to induction of SSAT and cytotoxicity, and also demonstrated impressive in vivo activity against multiple solid tumors [7, 21, 42] . As a result, phases I and II clinical trials have been completed with DENSpm [24, 30, 48, 56] ; however, to date DENSpm has not been eVective as a single agent. One of the potential problems limiting the eVectiveness of DENSpm may have been the daily administration schedule in most of its clinical trials. Such a schedule may have contributed to the observed does-limiting toxicities, thus impeding its clinical utility [30] . Therefore, the search has continued for a polyamine analogue with similar antineoplastic characteristics as the symmetrically substituted analogues, BESpm and DENSpm, but whose dosing schedule could be adjusted to allow eYcacy in the absence of serious dose-limiting toxicities.
CGC-11047 is a second-generation analogue of BESpm that is also symmetrically substituted, but that is conformationally restricted with a cis double bond between the central carbons (Fig. 1a) . CGC-11047 has shown positive results in the treatment of non-Hodgkin's lymphoma and is currently in several clinical trials. Treatment with CGC-11047 has demonstrated signiWcant growth inhibition in numerous tumor cell lines with ID 50 s as low as 50 nM in DU145 cells [43] . The growth inhibition was concurrent with analogue accumulation and decreased natural polyamines. However, the basis for this decrease in polyamine pools was not determined [43] . Consequently, despite some very promising results with CGC-11047, further studies on its biochemistry and potential mechanism of action are needed. Here we report on the eVects of CGC-11047 on four human lung cancer cell lines that represent the major forms of lung cancer, with an emphasis on biochemical mechanisms that may contribute to its antiproliferative eVects. Importantly, we demonstrate impressive antitumor eVects in vivo against a human xenograft model of lung adenocarcinoma that suggests that a clinical trial of CGC-11047 in lung cancer may be warranted. [ ]uM % of control (-seeding)   H157  A549  H69  H82   N  N  N  N  H  H  H  H   N  N  N  N  H  H  H  H  2 Cell culture and analysis of growth inhibition of human lung cancer cell lines
Materials and methods

Chemicals and reagents
The non-small cell cancer lines, NCI A549, NCI H157, and the small cell lung carcinoma lines, NCI H82 and NCI H69, were cultured as previously reported [15] . Cells were treated for the indicated times and concentrations. Cell growth was determined by standard trypan blue exclusion.
RNA puriWcation and Northern blot analysis
Extraction of total cellular RNA was performed using Trizol Reagent (Invitrogen) according to the manufacturersupplied protocol. For Northern blotting, total RNA (20 g) was separated on a denaturing 1.5% agarose gel containing 6% formaldehyde and transferred to Zetaprobe membrane (Bio-Rad) and hybridized to random primer-labeled PAOh1/SMO or SSAT cDNAs to determine SMO and SSAT expression [14, 52] . Blots were stripped and reprobed with a labeled 18S ribosomal cDNA as a loading control. Hybridized membranes were analyzed and images generated on a PhosphoImager using Image Quant software (Molecular Dynamics).
Analysis of polyamine content, SSAT, SMO, and ODC activity Intracellular polyamine concentrations were determined using the precolumn dansylation labeling, reverse phase high-pressure liquid chromatography method as reported by Kabra et al.
[32] using 1,7-diaminoheptane as an internal standard. Polyamine concentrations were reported as nmol/ mg protein for each sample, where lysate protein content was measured by the method of Bradford [9] . SSAT activity of cellular extracts was measured as previously published [11] . The SMO enzyme activity in the cell lysates was assayed as previously reported [53] . ODC activity was measured by the methods of Seely and Pegg [45] .
Western blot analysis
Total cell extracts were obtained by lysing cells on ice in RIPA buVer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 30 g/ml aprotinin, 100 M sodium orthovanadate, 10 g/ml PMSF) and insoluble material was pelleted at 12,000g for 20 min at 4°C. Thirty g of total protein was loaded per lane and separated on a 10% SDS-PAGE gels transferred electrophoretically to Immunoblot PVDF membrane (BioRad) for immunobloting. BrieXy, membranes were blocked for 1 hour in Odyssey blocking buVer, per manufacturer's instructions. The primary antibodies, an aYnity puriWed antisera to human SMO [3] . Tumor-bearing animals were then randomly sorted into two groups, control (n = 15) and treatment (n = 10). The treatment group received 100 mg/kg of CGC-11047 in 200 l HBSS by IP injection once a week for 3 weeks on and 1 week oV for a total of 14 weeks by intraperitoneal injection (IP). Control animals were injected with 200 l HBSS. Mice were weighed and tumor volumes were measured weekly. A Kaplan-Meier time to progression model was used to analyze the data with time to progression is deWned as time for the individual tumor to increase fourfold after the initiation of treatment. The log-rank test was used to determine statistical signiWcance.
Results
Inhibition of cell growth by CGC-11047
We have previously demonstrated diVerential sensitivity of human lung cancer phenotypes to speciWc polyamine analogues. SpeciWcally, human non-small cell lung cancer cells were found to be more sensitive to non-conformationally restricted analogues than small cell lung cancer cells and this diVerential sensitivity was associated with diVerential induction of polyamine catabolism [12, 15, 19] . To determine if a similar diVerential sensitivity was observed with the conformationally restricted CGC-11047, we compared cellular responses of two representative lines of small cell (H69 and H82) to two representative lines of non-small cell lung cancers (A549 and NCI-H157). CGC-11047 eVectively inhibited cell growth in both small cell and non-small cell lung cancers in a concentration-dependent manner after 96 h of treatment (Fig. 1b) . The IC 50 values for all cell lines ranged from 0.1 to 0.5 M, with the order of sensitivity A549 > H69 = H157 > H82. Although there appears to be some diVerences in sensitivity between the diVerent cell lines, these data indicate that CGC-11047 eVectively inhibits in vitro cell growth of multiple human lung cancer lines regardless of their phenotype.
EVects of CGC-11047 on polyamine metabolism
Several classes of polyamine analogues alter polyamine metabolism through multiple regulatory pathways [20] . The original basis for the synthesis of polyamine analogues for the treatment of cancer was based on the self-regulating nature of polyamine metabolism [39, 40] . Therefore, the eVects of CGC-11047 on polyamine metabolism were examined in the multiple lung cancer cell lines. The response to treatment with respect to alterations in polyamine metabolism were greater in the non-small cell phenotype than observed in the small cell phenotype, consistent with previous Wndings with other analogues [19] . In H157 and A549 cells, 24-h treatment with 10 M CGC-11047 up-regulated the polyamine catabolic enzyme spermidine/spermine N 1 -acetyltransferase (SSAT) and downregulated the polyamine biosynthetic enzyme ornithine decarboxylase (ODC). The induction of SSAT occurred at the level of mRNA (Fig. 2a) , protein (Fig. 2b, c) , and activity ( Fig. 3) , with SSAT enzyme activity increasing >1,000-fold in both A549 cells and H157 cells (Fig. 2) . By contrast, SSAT enzyme activity was not altered in H82 and H69 after 24-h treatment exposure to10 M of CGC-11047. Spermine oxidase (SMO) was signiWcantly induced only in the A549 cells (Figs. 2, 4) , as has been previously observed with other polyamine analogues [25] , demonstrating an approximate threefold increase in SMO activity after 24 h exposure to 10 M CGC-11047 (Fig. 4) .
The activity of one rate-limiting polyamine biosynthetic enzyme, ODC, demonstrated a reduction with CGC-11047 treatment to nearly undetectable levels in the H69, H157, and A549 cells, and to »20% of control in H82 cells. The decreases observed were more prominent in H157 and A549 cells since they have a higher basal level of ODC activity as compared to H69 and H82 cells (Fig. 5) .
The changes in polyamine concentrations resulting from analogue treatment are consistent with the observed changes in polyamine metabolic enzyme activities in the representative cell lines (Table 1) . SpeciWcally, the nonsmall cell lung cancer lines H157 and A549 demonstrated the greatest depletion of all three polyamines, consistent with their proWle of decreased ODC activity and increased polyamine catabolism (Figs. 2, 3, 4) , whereas the small cell line H69 was intermediate in its depletion of polyamine and H82 cells were the least aVected, again consistent with their proWle of polyamine metabolic enzyme activity in response to analogue treatment (Figs. 2, 3, 4) . It is also important to note that analogue accumulation by the individual cell lines was inversely proportional to the level of natural polyamine depletion (Table 1) . The in vivo therapeutic eVect of CGC-11047 was assessed using A549 xenografts in athymic nude nu/nu mutant mice. The A549 cell line was chosen for use in nude mice since in the in vitro setting CGC-11047 induced the greatest increase in polyamine catabolic enzyme activity, the greatest depletion of intracellular polyamines, and the largest growth inhibitory eVects of all the cell lines studied. Thirteen days after implantation of 1.0 £ 10 6 A549 cells the average tumor volume was 0.3 cm 3 (SD = 0.18) (n = 25) and average weight of the mice was 22.5 g (SD = 1.96). Mice were randomized into treated (n = 10) and control (n = 15) groups. Animals received intraperitoneal injections of 100 mg/kg of CGC-11047 in 200 l of Hanks balanced salt solution or of 200 l of Hanks alone. The treatment schedule was 100-mg/kg dose once weekly for 3 weeks followed a week of rest, for a total of 14 weeks. The once weekly dosing £3 every 4 weeks was selected since previous xenograft studies with other polyamine analogues have demonstrated once or twice weekly schedules are equivalent to the 5£ per week dosing, but with greater tolerability [31] . Treatment of established tumors with a weekly dose of CGC-11047 resulted in a signiWcant delay in progression (P · 0.0001, Fig. 6a) . By week seven all control animals had progressed (>fourfold increase in tumor starting volume), whereas only 30% of the treated animals had progressed. Even after 14 weeks of treatment, 30% of the treatment group had still not progressed and one mouse was found to be completely tumor free. Importantly, there were no overt signs of drug-induced toxicities and all treated animals continued to feed and gain weight normally (Fig. 6b) .
Discussion
The Our laboratory originally demonstrated a phenotype-speciWc response to polyamine analogues that was linked to increased polyamine catabolism, a Wnding that was subsequently corroborated by several other laboratories [11, 13-15, 22, 41] . SpeciWcally, analogues that were most eVective in inducing SSAT were found to be selective in their cytotoxic eVects against non-small cell lung cancer cells. As these studies were performed with the Wrst generation symmetrically substituted and second generation asymmetrically substituted polyamine analogues, we sought to determine if the symmetrically substituted, conformationally restricted polyamine analogue, CGC-11047 would demonstrate similar selectivity in vitro. Consistent with previous polyamine analogue studies, the small cell line H82 was the most resistant to CGC-11047 treatment [11, 12, 25] . However, at higher concentrations, it too was signiWcantly growth inhibited. The most sensitive line, the non-small cell line, A549 was also the line that demonstrated the greatest depletion of intracellular polyamines and the greatest accumulation of the analogue. Similarly, the other non-small cell line, H157, also demonstrated greater overall polyamine pool depletion and analogue accumulation than the two representative small cell lines. This greater perturbation of polyamine pools in the nonsmall cell lines is consistent with previous analogue studies and is most likely the result of the signiWcantly greater increase in polyamine catabolism induced by analogue treatment of the non-small cell lines as compared to the small cell lines, which demonstrate little or no induction of either SSAT or SMO in response to analogue treatment [11, 12, 25, 54] . Although analogue treatment of all cell types reduced ODC activity, most likely due to an increase in ODC antizyme production as previously demonstrated by Mitchell and colleagues [36, 37] , it is clear that the combination of decreased polyamine synthesis and increased polyamine catabolism leads to the greatest depletion of intracellular polyamines. This phenotypic diVerence in total polyamine depletion may have more signiWcance in vivo than in vitro, since in the in vivo setting the availability of circulating polyamines may be able to overcome the simple down regulation of ODC exhibited by the small cell lung cancer phenotype. The availability of circulating polyamines apparently caused decreased eYcacy in the clinical trial of 2-diXuoromethylornithine (DFMO) in small cell lung cancers [1, 2] . By contrast, in the non-small cell phenotype the increased polyamine catabolism may result in a greater growth inhibitory response in vivo by responding to analogue treatment with both a decrease in biosynthesis and an increase in catabolism. This may be particularly true for tumor types represented by the A549 cell line, in which nearly completed down regulation of ODC activity combined with highly induced catabolic enzymes, SSAT and SMO [25] . However, further in vivo testing in both phenotypes, with an analysis of the in vivo eVects of CGC-11047 on polyamine metabolism, will be required to determine if diVerential sensitivity based on phenotype-speciWc changes in polyamine catabolism exists in vivo.
Although preclinical studies with the Wrst generation, symmetrically substituted polyamine analogue BENSpm were encouraging [6, 7, 17 , 27], clinical trial results were less so [24, 30, 48, 56] . As previously mentioned, the less than desirable clinical results may have been a result of the inherent properties of BENSpm, and/or the daily dosing schedule used in those trials that showed GI and CNS doselimiting toxicities. We have previously demonstrated that daily or continuous administration of polyamine analogues is not necessary to achieve signiWcant tumor growth inhibition in vivo [31] . Therefore, to reduce the potential for toxicity, we utilized a single weekly dose of 100 mg/kg CGC-11047. This treatment schedule demonstrated eYcacy comparable to that reported for BENSpm given three times a day at 80 mg/kg for six consecutive days [7] . The single weekly dose of CGC-11047 signiWcantly delayed tumor progression without observable toxicity. As the single dose schedule was highly eVective in delaying tumor progression and even caused the complete regression of tumor in one of ten mice, and since there was no observable toxicity, alternative dosing schedules might be considered in future studies.
In summary, CGC-11047 represents a new conformationally restricted, short chain, symmetrically substituted polyamine analogue that demonstrates signiWcant growth inhibitory activity in multiple human cells lines representative of the major forms of human lung cancer. Interestingly, although there is clearly a phenotype-speciWc response with respect to the induction of polyamine catabolism exhibited between the non-small cell lung cancer phenotype (high induction) and the small cell (not induced), this diVerential response did not translate into signiWcant diVerence in growth response in vitro. However, as the non-small cell lines demonstrated greater polyamine depletion and greater accumulation of analogue, likely a result of increased catabolism, they may be expected to be more sensitive to analogue eVects in the in vivo setting. Importantly, CGC-11047 demonstrated highly signiWcant growth inhibition in a nude mouse model of human non-small cell lung demonstrating that further pre-clinical and, potentially, clinical trials in lung cancer are warranted.
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